Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone512-279-5100
Debt
Current Ratio2.42
Quick Ratio1.81
Price-To-Earnings
Sales & Book Value
Annual Sales$64.31 million
Price / Sales1.04
Price / Cash FlowN/A
Price / Book1.06
Profitability
Net Income$-27,290,000.00
Net Margins-56.22%
Return on Assets-33.12%
Miscellaneous
Employees213
OptionableNot Optionable
Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions
What is Apollo Endosurgery's stock symbol?
Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."
How were Apollo Endosurgery's earnings last quarter?
Apollo Endosurgery Inc (NASDAQ:APEN) posted its earnings results on Thursday, November, 8th. The biotechnology company reported ($0.45) EPS for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.11. The biotechnology company had revenue of $14.14 million for the quarter, compared to analyst estimates of $16.21 million. Apollo Endosurgery had a negative net margin of 56.22% and a negative return on equity of 71.73%. View Apollo Endosurgery's Earnings History.
When is Apollo Endosurgery's next earnings date?
What price target have analysts set for APEN?
3 equities research analysts have issued 1-year price targets for Apollo Endosurgery's shares. Their predictions range from $3.00 to $8.00. On average, they expect Apollo Endosurgery's stock price to reach $5.00 in the next year. This suggests a possible upside of 63.9% from the stock's current price. View Analyst Price Targets for Apollo Endosurgery.
What is the consensus analysts' recommendation for Apollo Endosurgery?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apollo Endosurgery.
What are Wall Street analysts saying about Apollo Endosurgery stock?
Here are some recent quotes from research analysts about Apollo Endosurgery stock:
- 1. Northland Securities analysts commented, "We are upgrading Perform rating. Our PT remains the same. The stock is down a lot from our original downgrade, and we think it is prudent to move to the sidelines. Our core concerns about the story, though, remain. Key Points Our updated outlook is based on the following: Business outlook remains weak. The company has already pre-announced Q4 revenue range of ~$15M (+/- a few hundred thousand), which was lower than consensus of ~$16M." (1/2/2019)
- 2. According to Zacks Investment Research, "Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company's product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas. " (12/21/2018)
Has Apollo Endosurgery been receiving favorable news coverage?
Media stories about APEN stock have been trending somewhat positive on Tuesday, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Apollo Endosurgery earned a news impact score of 1.9 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Apollo Endosurgery's key competitors?
Some companies that are related to Apollo Endosurgery include Nuvectra (NVTR), Pulse Biosciences (PLSE), Cytosorbents (CTSO), T2 Biosystems (TTOO), RenovaCare (RCAR), Sensus Healthcare (SRTS), RA Medical Systems (RMED), STRATA Skin Sciences (SSKN), Alphatec (ATEC), Arch Therapeutics (ARTH), iCAD (ICAD), Endologix (ELGX), Motus GI (MOTS), Invo Bioscience (IVOB) and CAS Medical Systems (CASM).
Who are Apollo Endosurgery's key executives?
Apollo Endosurgery's management team includes the folowing people:
- Mr. Todd Newton, CEO & Director (Age 55)
- Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
- Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
- Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
- Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner
How do I buy shares of Apollo Endosurgery?
Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apollo Endosurgery's stock price today?
One share of APEN stock can currently be purchased for approximately $3.05.
How big of a company is Apollo Endosurgery?
Apollo Endosurgery has a market capitalization of $68.31 million and generates $64.31 million in revenue each year. The biotechnology company earns $-27,290,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Apollo Endosurgery employs 213 workers across the globe.
What is Apollo Endosurgery's official website?
How can I contact Apollo Endosurgery?
Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]
MarketBeat Community Rating for Apollo Endosurgery (NASDAQ APEN)
MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
